Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix's proprietary antibodies and reagents.

22 Oct 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2009.

22 Oct 2009

ImmunoGen to host a conference call to discuss its financial results

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company’s financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen’s 2010 fiscal year.

22 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Inc. magazine has ranked Biocare Medical No. 2984 on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation. The company's sales growth was 93.1% from 2005-2008.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Cangene Corporation today reports financial results for the fiscal year ended July 31, 2009.

22 Oct 2009

Gates Foundation awards Vanderbilt University $100,000 for developing a malaria diagnostic test

Vanderbilt University announced Oct. 21 that it has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Associate Professor of Chemistry David Wright and Professor of Biomedical Engineering Rick Haselton, titled "Coffee Ring Stain Diagnostics for Malaria."

22 Oct 2009

Laureate Pharma signs development and manufacturing agreement to develop fusion protein products

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client.

22 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

Life science tool companies must consider multiple factors to develop strategies for future

Companies involved in the life science tools market must consider a multitude of technologies, economic drivers and societal trends in developing strategies for the future.

21 Oct 2009

BioWa, NKT Therapeutics sign licensing agreement

BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

21 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

NIH grant for Lpath to advance clinical development of its antibody therapeutics

The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.

21 Oct 2009

Bill & Melinda Gates Foundation's initiative to transform health in developing countries

The Bill & Melinda Gates Foundation today announced 76 grants of US$100,000 each to pursue bold ideas for transforming health in developing countries. The grants support researchers across 16 countries, including nine in Europe and Africa with ideas as diverse as using the power of sunlight to kill malaria-causing mosquito larvae and developing a device that repels mosquitoes without insecticides.

21 Oct 2009

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.

21 Oct 2009

Antibody News and Research

Further Reading

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Amorfix Life Sciences signs sale and distribution agreement with Cedarlane Laboratories

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

ImmunoGen to host a conference call to discuss its financial results

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Biocare Medical on the 2009 Inc. 5000 list of the fastest-growing private companies in the nation

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

HBO treatments may improve neurological outcome after traumatic brain injury

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Cangene Corporation announces financial results for the fiscal year ended July 31, 2009

Gates Foundation awards Vanderbilt University $100,000 for developing a malaria diagnostic test

Laureate Pharma signs development and manufacturing agreement to develop fusion protein products

Professor secures grant for further research on immunotherapy strategies

Life science tool companies must consider multiple factors to develop strategies for future

BioWa, NKT Therapeutics sign licensing agreement

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

NIH grant for Lpath to advance clinical development of its antibody therapeutics

Bill & Melinda Gates Foundation's initiative to transform health in developing countries

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo